Trading in Regeneron Common Stock Halted Advisory Committee of the U.S. Food and Drug Administration Reviewing PraluentA Injection Biologics License Application TARRYTOWN, N.Y., June 9, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. today announced that NASDAQ has halted trading of the company's common stock. The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration is meeting today to discuss the company's Biologics License Application for PraluentA Injection.
http://ift.tt/1cIJq1F
No comments:
Post a Comment